Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke

Joan Martí-Fàbregas, Santiago Medrano-Martorell, Elisa Merino, Luis Prats-Sánchez, Rebeca Marín, Raquel Delgado-Mederos, Pol Camps-Renom, Alejandro Martínez-Domenõ, Manuel Gómez-Choco, Lidia Lara, Ignacio Casado-Naranjo, David Cánovas, Maria José Torres, Marimar Freijo, Ana Calleja, Yolanda Bravo, Dolores Cocho, Ana Rodríguez-Campello, Beatriz Zandio, Blanca FuentesAlicia De Felipe, Laura Llull, José Maestre, Mariá Hernández, Moisès Garcés, Ana Maria De Arce-Borda, Ernest Palomeras, Manuel Rodríguez-Yáñez, Inma Diáz-Maroto, Marta Serrano, Jéssica Fernández-Domínguez, Jordi Sanahuja, Francisco Purroy, Marialuisa Zedde, Jordi Delgado-Mengual, Ignasi Gich

Research output: Contribution to journalArticle

Abstract

We investigated whether pre-treatment with statins is associated with surrogate markers of amyloid and hypertensive angiopathies in patients who need to start long-term oral anticoagulation therapy. A prospective multicenter study of patients naive for oral anticoagulants, who had an acute cardioembolic stroke. MRI was performed at admission to evaluate microbleeds, leukoaraiosis and superficial siderosis. We collected data on the specific statin compound, the dose and the statin intensity. We performed bivariate analyses and a logistic regression to investigate variables associated with microbleeds. We studied 470 patients (age 77.5 ± 6.4 years, 43.7% were men), and 193 (41.1%) of them received prior treatment with a statin. Microbleeds were detected in 140 (29.8%), leukoaraiosis in 388 (82.5%) and superficial siderosis in 20 (4.3%) patients. The presence of microbleeds, leukoaraiosis or superficial siderosis was not related to pre-treatment with statins. Microbleeds were more frequent in patients with prior intracerebral hemorrhage (OR 9.7, 95% CI 1.06-90.9) and in those pre-treated antiplatelets (OR 1.66, 95% CI 1.09-2.53). Prior treatment with statins was not associated with markers of bleeding-prone cerebral angiopathies in patients with cardioembolic stroke. Therefore, previous statin treatment should not influence the decision to initiate or withhold oral anticoagulation if these neuroimaging markers are detected.

Original languageEnglish
Article number1492
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke'. Together they form a unique fingerprint.

  • Cite this

    Martí-Fàbregas, J., Medrano-Martorell, S., Merino, E., Prats-Sánchez, L., Marín, R., Delgado-Mederos, R., Camps-Renom, P., Martínez-Domenõ, A., Gómez-Choco, M., Lara, L., Casado-Naranjo, I., Cánovas, D., Torres, M. J., Freijo, M., Calleja, A., Bravo, Y., Cocho, D., Rodríguez-Campello, A., Zandio, B., ... Gich, I. (2018). Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke. Scientific Reports, 8(1), [1492]. https://doi.org/10.1038/s41598-018-20055-3